AU2022280511A1 - Combined use of ubenimex and immune checkpoint inhibitor - Google Patents

Combined use of ubenimex and immune checkpoint inhibitor Download PDF

Info

Publication number
AU2022280511A1
AU2022280511A1 AU2022280511A AU2022280511A AU2022280511A1 AU 2022280511 A1 AU2022280511 A1 AU 2022280511A1 AU 2022280511 A AU2022280511 A AU 2022280511A AU 2022280511 A AU2022280511 A AU 2022280511A AU 2022280511 A1 AU2022280511 A1 AU 2022280511A1
Authority
AU
Australia
Prior art keywords
ubenimex
antibody
cancer
dosage
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022280511A
Other languages
English (en)
Inventor
Michiko AIJIMA
Naoko IGO
Daichi Nagai
Keiko Sekine
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Kayaku Co Ltd
Original Assignee
Nippon Kayaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Kayaku Co Ltd filed Critical Nippon Kayaku Co Ltd
Publication of AU2022280511A1 publication Critical patent/AU2022280511A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2022280511A 2021-05-28 2022-05-25 Combined use of ubenimex and immune checkpoint inhibitor Pending AU2022280511A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021-089984 2021-05-28
JP2021089984 2021-05-28
PCT/JP2022/021320 WO2022250070A1 (ja) 2021-05-28 2022-05-25 ウベニメクスと免疫チェックポイント阻害剤の併用

Publications (1)

Publication Number Publication Date
AU2022280511A1 true AU2022280511A1 (en) 2023-12-14

Family

ID=84229856

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022280511A Pending AU2022280511A1 (en) 2021-05-28 2022-05-25 Combined use of ubenimex and immune checkpoint inhibitor

Country Status (9)

Country Link
US (1) US20240082196A1 (https=)
EP (1) EP4349362A4 (https=)
JP (1) JPWO2022250070A1 (https=)
KR (1) KR20240016267A (https=)
CN (1) CN117412762A (https=)
AU (1) AU2022280511A1 (https=)
CA (1) CA3220025A1 (https=)
TW (1) TW202313091A (https=)
WO (1) WO2022250070A1 (https=)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
MY203926A (en) 2016-02-24 2024-07-24 Childrens Hospital Of Eastern Ontario Res Institute Inc Smc combination therapy for the treatment of cancer
WO2018112364A1 (en) * 2016-12-16 2018-06-21 Evelo Biosciences, Inc. Combination therapies for treating melanoma
WO2018178250A1 (en) 2017-03-31 2018-10-04 Boehringer Ingelheim International Gmbh Anticancer combination therapy
JP7257967B2 (ja) * 2017-05-01 2023-04-14 ザ チルドレンズ メディカル センター コーポレーション 抗ｐｄ１抗体試薬に関する方法および組成物
WO2019122941A1 (en) 2017-12-21 2019-06-27 Debiopharm International Sa Combination anti cancer therapy with an iap antagonist and an anti pd-1 molecule
US20210030703A1 (en) * 2018-03-12 2021-02-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of caloric restriction mimetics for potentiating chemo-immunotherapy for the treatment of cancers
SI4076385T1 (sl) * 2019-12-20 2026-04-30 Formycon Ag Formulacije protiteles anti-pd1

Also Published As

Publication number Publication date
KR20240016267A (ko) 2024-02-06
JPWO2022250070A1 (https=) 2022-12-01
WO2022250070A1 (ja) 2022-12-01
EP4349362A4 (en) 2025-05-14
EP4349362A1 (en) 2024-04-10
CA3220025A1 (en) 2022-12-01
US20240082196A1 (en) 2024-03-14
CN117412762A (zh) 2024-01-16
TW202313091A (zh) 2023-04-01

Similar Documents

Publication Publication Date Title
AU2021202416B2 (en) Use of plinabulin in combination with immune checkpoint inhibitors
AU2004294842B2 (en) Medicine containing genetically modified antibody against chemokine receptor CCR4
AU2026200529A1 (en) Methods, therapies and uses for treating cancer
KR20170003575A (ko) 비-소세포 폐암을 치료하기 위한 항-ｂ7-ｈ1 및 항-ｃｔｌａ-4 항체
US20220401465A1 (en) Uses of nad+ and/or nad+ inhibitors and/or nad+ agonists and combination preparation thereof
KR20100041849A (ko) Ｃｄ200에 대한 항체와 면역 반응의 저해에서 이들의 용도
AU2026201847A1 (en) Methods, therapies and uses for treating cancer
JP2023036999A (ja) 免疫応答を調節するためのオキサビシクロヘプタン
US20250073230A1 (en) Use of plinabulin in combination with immune checkpoint inhibitors
CA3147071A1 (en) Methods of treatment
US20240082196A1 (en) Combined use of ubenimex and immune checkpoint inhibitor
EP4058052A1 (en) Cd200 receptor antagonist binding molecules
WO2024014523A1 (en) Anti-aqp3 antibody cancer therapy
KR20260022961A (ko) 암 치료를 위한 ioa-244, pd-1 또는 pd-l1 억제제 및 화학요법제의 병용
JP2025530188A (ja) 膀胱がんの治療において使用するための改変ｔ細胞
CN116077645A (zh) 抗-pd-1抗体及其在制备治疗非小细胞肺癌患者的药物中的用途
HK40099485A (zh) 普那布林联合免疫检查点抑制剂的用途
NZ750444B2 (en) Use of plinabulin in combination with immune checkpoint inhibitors

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ COMBINED USE OF UBENIMEX AND IMMUNE CHECKPOINT INHIBITOR